Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors

Behan, K., Cutts, C. and Tett, S. E. (2005) Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors. European Journal of Clinical Pharmacology, 61 1: 55-58. doi:10.1007/s00228-004-0865-6


Author Behan, K.
Cutts, C.
Tett, S. E.
Title Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors
Journal name European Journal of Clinical Pharmacology   Check publisher's open access policy
ISSN 0031-6970
Publication date 2005
Sub-type Article (original research)
DOI 10.1007/s00228-004-0865-6
Volume 61
Issue 1
Start page 55
End page 58
Total pages 4
Editor R. Dahlqvist
Place of publication Germany
Publisher Springer-Verlag
Collection year 2005
Language eng
Subject C1
320503 Clinical Pharmacology and Therapeutics
730209 Rural health
Formatted abstract
Objective This study compared the changes over time in the volume of prescriptions of COX-2 selective inhibitors between rural and urban Queensland to reveal any difference in the uptake of the prescribing of these new drugs between two geographically distinct areas.
Methods This study used data from an administrative claims database. Dispensing data were obtained for celecoxib and rofecoxib in two areas, one rural and one urban, defined by postcodes. The numbers of consumers in these areas were similar and they were served by similar numbers of general practitioners. The number of defined daily doses (DDDs) of celecoxib and rofecoxib dispensed at specific times was calculated.
Results Statistical analysis revealed no significant difference between the total numbers of DDDs of COX-2-selective non-steroidal anti-inflammatory drugs dispensed in the rural and urban groups over the period August 2000 to December 2002 (P=0.81). The rate of uptake of usage was also clearly similar between the urban and the rural groups. Total usage peaked in August 2000 in both groups (urban 39 DDD/1,000 people per day; rural 37 DDD/1,000 people per day), coinciding with the pharmaceutical benefits scheme (subsidized) listing of celecoxib. The number of DDDs declined dramatically in the following month, and then peaked again in May 2002 (urban 34, rural 36). The number of DDDs then steadily decreased in both areas after October 2002.
Conclusion The results suggest that the marketing of the new COX-2 inhibitors and the patientsrsquo anticipation of a safe and effective treatment have overcome the geographical boundaries of Queensland. Both areas had very high rates of uptake of the prescribing of these new drugs.
Keyword Pharmacology & Pharmacy
General-practitioners
Benefits
Doctors
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2006 Higher Education Research Data Collection
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 05:49:19 EST